Weekly Digest – July 2025 Weekly Digest – July 2025 23 July 2025: Blenrep (Belantamab mafodotin) combinations approved in Canada for the treatment of relapsed/refractory multiple myeloma Health Canada approved GSK’s Blenrep in combination with Bortezomib + Dexamethasone or Pomalidomide […]
Weekly Digest – July 2025 Weekly Digest – July 2025 24 July 2025: Mirvetuximab soravtansine approved in UK to treat adult patients who have ovarian, fallopian tube or primary peritoneal cancer The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has […]
Weekly Digest – July 2025 Weekly Digest – July 2025 24 July 2025: Blenrep (Belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma Blenrep has been approved in the EU for use with BVd or BPd regimens […]
